Over the last 12 months, Castle Biosciences insiders reported no purchases and 24 sales totaling $4.2M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 16,114 | $31.08 | $501K | -45.1% | plan · 6 tranches · indirect |
| Aug 5, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 22,902 | $31.06 | $711K | -51.6% | plan · 3 tranches |
| Aug 3, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 8,586 | $29.77 | $256K | -39.3% | plan · 3 tranches |
| Aug 3, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 19,040 | $29.21 | $556K | -19.4% | plan · 4 tranches |
| Aug 3, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 11,502 | $30.29 | $348K | -29.9% | plan · 4 tranches · indirect |
| Aug 3, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 17,144 | $30.28 | $519K | -44.4% | plan · 2 tranches |
| Jul 27, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $24.16 | $88K | -23.5% | plan · 12 tranches · indirect |
| Jul 27, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $24.16 | $150K | -22.4% | plan · 2 tranches |
| Jul 14, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $22.92 | $83K | -23.1% | plan · 6 tranches · indirect |
| Jul 14, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 550 | $22.92 | $13K | -2.5% | plan |
| Jul 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $24.29 | $88K | -22.7% | plan · 6 tranches · indirect |
| Jul 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $24.29 | $151K | -22.4% | plan |
| Jul 1, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 8,586 | $24.42 | $210K | -28.2% | plan · 2 tranches |
| Jun 16, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 8,587 | $20.71 | $178K | -22% | plan |
| Jun 15, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $20.66 | $75K | -22.3% | plan · 6 tranches · indirect |
| Jun 15, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 550 | $20.66 | $11K | -2.5% | plan |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 278 | $20.86 | $6K | -14.3% | plan · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 278 | $20.86 | $6K | -14.3% | plan · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 278 | $20.86 | $6K | -14.3% | plan · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 278 | $20.86 | $6K | -14.3% | plan · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 1,153 | $20.86 | $24K | -3% | plan · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 1,357 | $20.86 | $28K | -3% | plan · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $20.86 | $130K | -22.4% | plan |
| Nov 24, 2025 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 1,301 | $38.39 | $50K | -1.6% | plan · late |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CSTL feed.